Mallinckrodt stands alone as $2.1b pharma business
This article was originally published in Scrip
Executive Summary
Mallinckrodt Pharmaceuticals is officially a stand-alone entity now that the medical device and supply company Covidien has completed the spin-out of its 5,500-employee pharma business with more than $2 billion in annual net sales.